{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:28:21Z","timestamp":1781519301992,"version":"3.54.1"},"reference-count":32,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T00:00:00Z","timestamp":1650326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009812","name":"Chinese Society of Clinical Oncology","doi-asserted-by":"publisher","award":["Y\u2010XD2019\u2010124"],"award-info":[{"award-number":["Y\u2010XD2019\u2010124"]}],"id":[{"id":"10.13039\/501100009812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007162","name":"Guangdong Science and Technology Department","doi-asserted-by":"publisher","award":["202002030205"],"award-info":[{"award-number":["202002030205"]}],"id":[{"id":"10.13039\/501100007162","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib\u2010based combination therapy are important salvage options for patients with relapsed\/refractory (R\/R) MCL. The real\u2010world efficacy and safety profile of the two strategies in Chinese patients with R\/R MCL remain unclarified.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the present study, data of 121 R\/R MCL patients who received either ibrutinib monotherapy (<jats:italic>N\u2009=<\/jats:italic>68) or ibrutinib combination therapy (<jats:italic>N\u2009=<\/jats:italic>53) in 13 medical centers in China were retrospectively reviewed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With a median follow\u2010up of 20.5\u2009months, the overall response rate was 60.3% versus 84.9% (<jats:italic>p<\/jats:italic>=\u00a00.003), complete remission rate was 16.2% versus 43.4% (<jats:italic>p<\/jats:italic>&lt;\u20090.001), and median progression\u2010free survival (PFS) was 18.5\u2009months (95% confidence interval [CI], 12.1\u201321.8) vs. 30.8\u2009months (95% CI, 23.5\u2010NR) (hazard ratio, 0.53 [95% CI, 0.30\u20130.93];<jats:italic>p<\/jats:italic>=\u00a00.025), with ibrutinib monotherapy and ibrutinib\u2010based combination therapy, respectively. Subgroup analysis showed that patients with male gender, no refractory disease, Ki67 &lt;30%, previous line of therapy\u00a0=\u00a01, non\u2010blastoid subtype, and the number of extranodal sites involved &lt;2 might benefits more from the combination therapy. Treatment\u2010emergent adverse events were similar, except for a higher incidence of all grade neutropenia in the ibrutinib combination group (12.7% vs. 32.0%,<jats:italic>p<\/jats:italic>= 0.017).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ibrutinib combination therapy demonstrated potentially superior efficacy and comparable tolerability to ibrutinib monotherapy. Ibrutinib\u2010based combination therapy could be one of the prominent treatment options for R\/R MCL patients.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cam4.4765","type":"journal-article","created":{"date-parts":[[2022,4,19]],"date-time":"2022-04-19T11:32:53Z","timestamp":1650367973000},"page":"4134-4145","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed\/refractory mantle cell lymphoma: A multicenter study"],"prefix":"10.1002","volume":"11","author":[{"given":"Yuchen","family":"Zhang","sequence":"first","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7447-7026","authenticated-orcid":false,"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Hematology Peking University Third Hospital Beijing P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Oncology West China Hospital, Sichuan University Chengdu P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hematology Guangdong Province Traditional Chinese Medical Hospital Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[{"name":"Division of Lymphoma, Department of Clinical Oncology Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueli","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hematology The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Hematology The Second Affiliated Hospital of Guangzhou Medical University Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ru","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology Nanfang Hospital of Nanfang Medical University Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma Tianjin Medical University Cancer Hospital and Institute Tianjin P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, Union Hospital, Tongji Medical College Huazhong University of Science and Technology Wuhan P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lie","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematology Hainan General Hospital Haikou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[{"name":"Myeloma and Lymphoma Research Center Second Affiliated Hospital of Dalian Medical University Dalian P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Hematology Hainan Cancer Hospital Haikou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Hematologic Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9730-9917","authenticated-orcid":false,"given":"Zhiming","family":"Li","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Huang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5447-3282","authenticated-orcid":false,"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"},{"name":"Department of Medical Oncology Sun Yat\u2010sen University Cancer Center Guangzhou P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61272"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-00855-9"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25487"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25215"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2380"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17363"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16739"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12150"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2565"},{"key":"e_1_2_10_14_1","doi-asserted-by":"crossref","unstructured":"JanssensA BernemanZ BronD et al.Clinical outcomes with single\u2010agent ibrutinib for relapsed\/refractory (R\/R) mantle cell lymphoma (MCL): interim analysis (IA) of the Belgian Ibrutinib Real\u2010World Data (BiRD) study. 24th European Hematology Association Annual Congress 2019.","DOI":"10.1002\/j.2572-9241.2019.tb00093.x"},{"key":"e_1_2_10_15_1","unstructured":"SlamaB DelmerA CartronG et al.French ibrutinib observational study (FIRE): real\u2010world study of ibrutinib treatment for mantle cell lymphoma (MCL) in France. 24th European Hematology Association Annual Congress 2019."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15567"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30018-8"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1715519"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008727"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2012.05.024"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13149"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1304"},{"key":"e_1_2_10_26_1","first-page":"6679","article-title":"Synergistic cytotoxicity of bendamustine and the BTK inhibitor in a mantle cell lymphoma cell line","volume":"35","author":"Hagiwara K","year":"2015","journal-title":"Anticancer Res"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30261-4"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0477-9"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-095331"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.214056"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9500"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-018-0022-5"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139955"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4765","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.4765","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.4765","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T12:56:53Z","timestamp":1727009813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.4765"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,19]]},"references-count":32,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/cam4.4765"],"URL":"https:\/\/doi.org\/10.1002\/cam4.4765","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,19]]},"assertion":[{"value":"2021-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}